References
- Hulleman E, Helin K. Molecular mechanisms in gliomagenesis. Adv Cancer Res 2005;94:1–27.
- Ozaki T, Kubo N, Nakagawara A. p73-binding partners and their functional significance. Int J Proteomics 2010;2010:283863.
- Dong S, Pang JC, Hu J, Zhou L, Ng H. Transcriptional inactivation of TP73 expression in oligodendroglial tumors. Int J Cancer 2002;98:370–5.
- Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res 2004;2:371–86.
- Ichimura K, Vogazianou AP, Liu L, et al. 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene 2008;27:2097–108.
- Alonso ME, Bello MJ, Lomas J, et al. Absence of mutation of the p73 gene in astrocytic neoplasms. Int J Oncol 2001;19: 609–12.
- Bisso A, Collavin L, Del Sal G. P73 as a pharmaceutical target for cancer therapy. Curr Pharm Des 2011;17:578–90.
- Flores ER, Sengupta S, Miller JB, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005;7: 363–73.
- Liu F, Liu L, Li B, et al. p73 G4C14-A4T14 polymorphism and cancer risk: a meta-analysis based on 27 case-control studies. Mutagenesis 2011;26:573–81.
- Zawacka-Pankau J, Kostecka A, Sznarkowska A, Hedström E, Kawiak A. p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach? Cell Cycle 2010;9:720–8.
- Watanabe T, Huang H, Nakamura M, et al. Methylation of the p73 gene in gliomas. Acta Neuropathol 2002;104:357–62.
- Loiseau H, Arsaut J, Demotes-Mainard J. P73 gene transcripts in human brain tumors: Overexpression and altered splicing in ependymomas. Neurosci Lett 1999;263:173–6.
- Kamiya M, Nakazato Y. The expression of p73, p21 and MDM2 proteins in gliomas. J Neurooncol 2002;59:143–9.
- Liu G, Nozell S, Xiao H, Chen X. DeltaNp73beta is active in transactivation and growth suppression. Mol Cell Biol 2004;24:487–501.
- Buhlmann S, Pützer BM. DNp73 a matter of cancer: mechanisms and clinical implications. Biochim Biophys Acta 2008;1785:207–16.
- Ozaki T, Nakagawara A. P73, a sophisticated P53 family member in the cancer world. Cancer Sci 2005;96:729–37.
- Ben-Yehoyada M, Ben-Dor I, Shaul Y. c-Abl tyrosine kinase selectively regulates p73 nuclear matrix association. J Biol Chem 2003;278:34475–82.
- Melino G, Lu X, Gasco M, Crook T, Knight RA. Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci 2003;28:663–70.
- Urist M, Tanaka T, Poyurovsky MV, Prives C. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev 2004;18:3041–54.
- Alonso MM, Alemany R, Fueyo J, Gomez-Manzano C. E2F1 in gliomas: a paradigm of oncogene addiction. Cancer Lett 2008;263:157–63.
- Stiewe T, Pützer BM. Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ 2002;9:237–45.
- Rufini A, Agostini M, Grespi F, et al. p73 in cancer. Genes Cancer 2011;2:491–502.
- Bencokova Z, Pauron L, Devic C, et al. Molecular and cellular response of the most extensively used rodent glioma models to radiation and/or cisplatin. J Neurooncol 2008;86:13–21.
- Bailey SG, Sanchez-Elsner T, Stephanou A, Cragg MS, Townsend PA. Regulating the genome surveillance system: miRNAs and the p53 super family. Apoptosis 2010;15:541–52.
- Ozaki T, Hosoda M, Miyazaki K, et al. Functional implication of p73 protein stability in neuronal cell survival and death. Cancer Lett 2005;228:29–35.
- Marabese M, Vikhanskaya F, Broggini M. P73: a chiaroscuro gene in cancer. Eur J Cancer 2007;43:1361–72.
- Conforti F, Sayan AE, Sreekumar R, Sayan BS. Regulation of p73 activity by post-translational modifications. Cell Death Dis 2012;3:e285.
- Stamatakos M, Palla V, Karaiskos I, et al. Cell cyclins: triggering elements of cancer or not? World J Surg Oncol 2010;8:111.
- Zaika A, Irwin M, Sansome C, Moll UM. Oncogenes induce and activate endogenous p73 protein. J Biol Chem 2001;276: 11310–6.
- Merlo P, Fulco M, Costanzo A, et al. A role of p73 in mitotic exit. J Biol Chem 2005;280:30354–60.
- Morales AG, Pezuk JA, Brassesco MS, et al. BUB1 and BUBR1 inhibition decreases proliferation and colony formation, and enhances radiation sensitivity in pediatric glioblastoma cells. Childs Nerv Syst 2013;29:2241–8.
- Di Como CJ, Gaiddon C, Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999;19:1438–49.
- Gross MW, Kraus A, Nashwan K, et al. Expression of p53 and p21 in primary glioblastomas. Strahlenther Onkol 2005;181:164–71.
- Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene 2008;27:6194–206.
- Ito H, Kanzawa T, Miyoshi T, et al. Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status. Hum Gene Ther 2005;16:685–98.
- Gupta RK, Tripathi R, Naidu BJ, Srinivas UK, Shashidhara LS. Cell cycle regulation by the pro-apoptotic gene Scotin. Cell Cycle 2008;7:2401–8.
- Terrinoni A, Ranalli M, Cadot B, et al. p73-alpha is capable of inducing scotin and ER stress. Oncogene 2004;23:3721–5.
- Allocati N, Di Ilio C, De Laurenzi V. p63/p73 in the control of cell cycle and cell death. Exp Cell Res 2012;318:1285–90.
- Kleber S, Sancho-Martinez I, Wiestler B, et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008;13:235–48.
- Shinohara H, Yagita H, Ikawa Y, Oyaizu N. Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation. Cancer Res 2000;60:1766–72.
- Choi K. Induction of intercellular adhesion molecule-1 by Fas ligation: proinflammatory roles of Fas in human astroglioma cells. Neurosci Lett 2003;352:21–4.